LupusForum Highlights Brochure ACR2022

ACR 2022
Congress Preview
Lupus
Chair’s Introduction
Dear Colleagues,
Welcome to the Lupus Forum ACR 2022 Congress Preview, your companion to this year’s Convergence. ACR 2022 marks 1 year of
the Lupus Forum. In the last 12 months we have brought you monthly publication summaries, congress reviews from ACR 2021 and
EULAR 2022, and numerous podcasts exploring key topics in greater depth. It gives me great pleasure to continue highlighting the
new data in Lupus – I hope you find my Chair’s picks useful.
The Treatment Poster I session on Saturday includes data on belimumab in SLE, comparing the risk of infection vs oral
immunosuppressants (349), and assessing its effect on kidney outcomes (352). There are two interesting posters on the long-term
use of voclosporin in lupus nephritis, one from the AURORA continuation study focused on patients in Class V (355), and one
assessing safety and efficacy in Hispanic and Latino patients (358). Two posters on novel therapies in SLE complete my picks for
Saturday: The Phase 2 results of BIIB059 from the LILAC (Part A) study (364) and JBT-101/lenabasum (371).
Sunday sees another poster session covering plenty of lupus content. Treatment Poster II includes observation of the rapid efficacy
of anifrolumab in CLE in relation to changes in transcriptomic and cellular biomarkers (974), as well as a pooled post-hoc analysis of
five Phase 3 trials to assess the effects of belimumab on skin in SLE (979). This is a great session for data on novel therapies, with
posters on ALPN-303 (987), efavaleukin alfa (989), deucravacitinib (1000) and cenerimod (1002), all for SLE, and zetomipzomib (992)
for lupus nephritis.
On Monday, we have two abstracts of interest in the SLE – Treatment abstract session, where the results from the 3-year TULIP
extension study of anifrolumab will be presented (1652), as well as the Phase 2b results from the dose-finding trial of cenerimod
(1656). In the SLE – Diagnosis, Manifestation, and Outcomes Poster III: Outcomes session there are two posters I would draw your
attention to. Firstly, the skin implication on HRQoL in patients with SLE (2089), and finally, one of the late breakers, the results of the
Phase 3 study into telitacicept (L07).
We add new content to the Lupus Forum regularly, so make sure you register for updates at lupus-forum.com or keep up to date by
following us on Twitter @LupusForum and on LinkedIn by searching “Lupus Forum”.
I hope you find our selection of highlights useful and that you enjoy the Convergence.
Kind regards,
Ed Vital
Associate Professor, University of Leeds
Key Lupus Content
Saturday, 12 November 2022
Chair’s Picks
13:00– SLE – Diagnosis, Manifestations, and Outcomes Poster I: Diagnosis
15:30
329
Scoring Personalized Molecular Portraits Identify Systemic Lupus Erythematosus Subtypes and Predict Individualized Drug
Responses, Symptomatology and Disease Progression
13:00– Treatment Poster I
15:30
347 Real-world Effectiveness of Belimumab in Patients with SLE in the United States
348
349
Significant Improvement in Cutaneous Lupus Erythematosus with or without Systemic Lupus Erythematosus with Belimumab
Use – A Systematic Review and Meta-analysis
Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-renal Systemic Lupus
Erythematosus
350 Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
351
The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus:
A Single-center Retrospective Study
352 The Effect of Belimumab (BEL) on Kidney Outcomes in SLE: Results of a Large Integrated Analysis
355 Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
356
Early Reductions in Proteinuria with Voclosporin Treatment Across Lupus Nephritis Biopsy Classes: Pooled Data from the
AURA-LV and AURORA 1 Trials
357 Voclosporin is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
358 Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis
360
Longitudinal Variation of Proteomic Biomarkers that Correlate with Efficacy Endpoints: Results from a Phase 3 Trial of
Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus
361 Gene Expression Pathways Modulated by Anifrolumab in Systemic Lupus Erythematosus
364
Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): Exploratory
Analyses of the Phase 2, Randomized, Double-blind, Placebo-controlled LILAC Study (Part A)

Chair’s Picks
365
Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus
(CLE): Exploratory Analyses of the Phase 2, Randomized, Double-blind, Placebo-controlled LILAC Study (Part B)
368 Which Are the Best Therapeutic Strategies for Systemic Lupus Erythematosus Severe Thrombocytopenia? A Ten Year Analysis
371
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of
JBT-101/Lenabasum in Systemic Lupus Erythematosus, an Autoimmunity Centers of Excellence Study (ALE09)
Sunday, 13 November 2022
09:00–
10:30
974
975
976
977
978
979
982
987
Treatment Poster II
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete
Changes in Transcriptomic and Cellular Biomarkers
Modulation of T, B, and Innate Cell-associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to
Severe SLE
Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four
Randomised Clinical Trials
Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL
Summary of Lupus Efficacy (Be-SLE)
Belimumab After Rituximab Targets IgA2 Anti-dsDNA Antibody Production and Shifts Repopulating B-cells Towards an
Anergic, Non-pathogenic Phenotype in Systemic Lupus Erythematosus
Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3,
Randomized, Placebo-controlled Clinical Trials
Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients
with Systemic Lupus Erythematosus
A Randomized Placebo-controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and
Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus
and Other Autoantibody-associated Diseases
989 Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
992
996
1000
Interim Results from the Phase 2 MISSION Study Evaluating Zetomipzomib (KZR-616), a First-in-class Selective
Immunoproteasome Inhibitor for the Treatment of Lupus Nephritis
Tapering of Corticosteroids or Immunosuppressive Therapy in Stable SLE: A Comparison of Complete Remission, Clinical
Remission and Lupus Low Disease Activity State in Protection Against Flares
Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity:
Pharmacodynamic Analysis from the Phase 2 PAISLEY Study
1001 Effect of Atacicept on Renal Function in Patients with Systemic Lupus Erythematosus (SLE)
1002
Investigation of Pharmacodynamic Biomarkers in a Phase 2b Study in Patients with Moderate to Severe SLE Treated with the
S1P1 Receptor Modulator Cenerimod
Monday, 14 November 2022
09:00–
10:30
1652
Abstract Session
SLE – Treatment
Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter,
Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study
1656
Efficacy and Safety of Cenerimod in Patients with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Multicenter,
Randomized, Parallel-group, Double-blind, Placebo-controlled, Dose-finding Phase 2b Trial
13:00– SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes
15:00
2089 The Implication of Skin Involvement on Health-related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
2090
13:00–
15:00
L07
Evaluation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) vs. SLEDAI-2K Glucocorticoids
(SLEDAI-2KG) on Patient Health-related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE)
(L07–L17) Late-Breaking Abstract Poster
Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-inducing
Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study
Developed
under the
auspices of:
Supported with
an educational
grant from: